|Bid||118.10 x 800|
|Ask||118.10 x 900|
|Day's Range||116.78 - 118.24|
|52 Week Range||77.09 - 132.13|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||37.74|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.58 (1.99%)|
|1y Target Est||124.93|
A new survey of more than 50,000 workers from Forbes and Statista claims that the best place to work at is grocery store Trader Joe’s followed by Southwest and Eli Lilly. Yahoo Finance’s Alexis Christoforous and Brian Sozzi discuss.
Eli Lilly and Co. said Thursday it is working with doctors to ensure patients who are currently receiving Lartruvo, a soft-tissue sarcoma therapy being pulled from the market following the failure of a late-stage trial, will still be able to receive the drug if they have been told of the drug's risks and trial outcomes and wish to continue. The company announced in January that a Phase 3 trial of Lartruvo as a combination therapy with doxorubicin in patients with advanced soft-tissue sarcoma did not improve survival compared with standard of care. The drugmaker is now working on facilitating a smooth withdrawal of the drug from the market for advanced soft tissue sarcoma. No new patients will receive the drug outside of those participating in ongoing trials, the company said. Shares of Eli Lilly have gained 2% in the year to date, while the S&P 500 has gained 16.8%.
Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market INDIANAPOLIS , April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.
Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches after the company found the treatment was unlikely to meet the main goal of a late-stage trial. The drug, known generically as fremanezumab, competes with rival treatments from Eli Lilly & Co and Amgen Inc . Lilly in November received the U.S. Food and Drug Administration's "breakthrough" status for its migraine drug Emgality in treating episodic cluster headaches.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor® and Vancocin®, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company. Under the terms of the agreement, Lilly will receive a deposit of $75 million, followed by a payment of $300 million upon successful closing of the transaction. As part of the transaction, all employees at the Ceclor manufacturing facility and certain employees from shared functions will be offered the opportunity to remain at the facility and continue to work with Eddingpharm.
sank about 1% to $114.26 Monday even though the company said its drug Taltz saw positive results from a Phase 3 study. Eli Lilly said the Phase 3 study of Taltz met both primary and secondary endpoints in treating a subset of patients with axial spondyloarthritis, or axSpA, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton and is estimated to affect 4.5 million adults worldwide. Taltz met the primary endpoint at both week 16 and week 52, the Indianapolis-based company said, demonstrating a statistically significant improvement in the signs and symptoms of nr-axSpA.
It might be of some concern to shareholders to see the Eli Lilly and Company (NYSE:LLY) share price down 10% in the last month. Looking further back, the stock has generated good profits over five years. It has return...
Lilly and partner Pfizer Inc. (NYSE: PFE) said in a Thursday news release the Phase 3 study intended to evaluate tanezumab in 2.5mg and 5mg doses for its long-term safety and 16-week efficacy relative to nonsteroidal anti-inflammatory drugs, or NSAIDs, in patients with moderate-to-severe osteoarthritis of the hip or knee produced mixed results. Tanezumab is an investigational monoclonal antibody that selectively targets, binds and inhibits nerve growth factor, or NGF, which increases as a result of injury, inflammation or in chronic pain states.
Shares of Eli Lilly and Co. were down 3.4% in premarket trade Monday despite the company's announcement that a Phase 3 study of its drug Taltz had met both primary and secondary endpoints in treating a subset of patients with axial spondyloarthritis. Patients on Taltz, a monoclonal antibody, showed a statistically significant improvement in symptoms 16 and 52 weeks after starting treatment, the company said. The drug's safety profile remained the same as before -- Taltz has been shown to increase a person's risk of getting infections and some patients have reported serious hypersensitivity reactions and exacerbations of Crohn's disease and ulcerative colitis. Taltz is currently approved to treat psoriatic arthritis and moderate-to-severe plaque psoriasis. Earlier Monday morning, Lilly announced a licensing and research collaboration with Avidity Biosciences, Inc., a privately-held biotech company that has developed a platform using properties of monoclonal antibodies and oligonucleotide-based therapeutics to target genetic diseases. Under the terms of the agreement, Lilly will pay Avidity $20 million upfront and make an additional investment in the company of $15 million. Avidity will be eligible to receive up to $405 million in milestone payments, as well as tiered royalties depending on product sales. Sharse of Eli Lilly have fallen 0.5% so far this year, while the S&P 500 has gained 15.9%.
INDIANAPOLIS , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study ...
INDIANAPOLIS and LA JOLLA, Calif., April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications.
This selloff, which actually started at the end of the last quarter, has taken apart the managed care stocks, the drug stocks, the devices and finally the biotechs. No matter, the fact is that every day there were moments in this tsunami where you simply couldn't believe the torrent of selling, but you most likely didn't even know what was going to spring a leak next. Being diversified is defensive, as we know: If you had all health care bought in March, you might be done for 2019! But I think, more important and less talked about, it allows you to be offensive, too.
Shares of drug makers Pfizer Inc. and Eli Lilly & Co. declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals. Pfizer shares declined 1% after hours, following a 1.3% decline to close at $39.38 in the regular trading session. Lilly shares fell 1.9% after hours, following a 1.1% close lower at $115.20. The companies said that a late-stage study of their drug tanezumab at 5 mg did not show a statistically significant improvement in overall osteoarthritis symptoms compared with nonsteroidal anti-inflammatory drugs. A 2.5 mg dose did not show a statistically significant improvement in pain, physical function or patients' overall assessment, the companies said. "We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab," said Ken Verburg, Pfizer's tanezumab development team leader, in a statement. "We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities."
A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday. The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster. The study tested the treatment in two doses, 2.5 mg and 5 mg, comparing the long-term joint safety and effectiveness at the end of 16 weeks with painkillers that are normally prescribed to patients.
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
(LLY) stock was lower on Thursday following a downgrade from Guggenheim, which argues that the drugmaker’s strong growth outlook is already baked into the shares. Many health-care stocks had a good 2018 as tech lost its luster and the market swoon sent investors scrambling for safety, but few have fared better than Eli Lilly. Although the stock is up just under 9% in 2019, slightly trailing the broader market’s gains, it has risen 58% in the trailing 12-month period.
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors